XENE ▲ +3.1% - Xenon Pharmaceuticals Inc.
$XENE - Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
29-OCT-2026 08:30 AM ET
Share this post
More filings for $XENE
XENE - Xenon Pharmaceuticals Inc. - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026XENE ▲ +2.0% - Xenon Pharmaceuticals Inc.Nov 9, 2026XENE - Xenon Pharmaceuticals Inc. - SEC Filing Update (06-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 6, 2026XENE - Xenon Pharmaceuticals Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026XENE ▲ +1.6% - Xenon Pharmaceuticals Inc.Nov 3, 2026XENE ▲ +0.5% - Xenon Pharmaceuticals Inc.Nov 2, 2026
View full $XENE filing history →💬 Comments
Loading comments…
Leave a comment
